Drug Profile


Alternative Names: Anti-mCEA monoclonal antibody PR1A3; Monoclonal antibody PR1A3

Latest Information Update: 27 Jun 2005

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Antisoma; Cancer Research UK
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Immunostimulants; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 27 Jun 2005 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
  • 22 Dec 1998 Preclinical development for Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top